Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives

Definitions

• This invention relates to the use of a phenoxyacetic acid derivative of the formula (I): wherein R is a C1-C6-alkyl group or a C1-C6-alkoxy-substituted C1-C6-alkyl group and X is a halogen atom, or a pharmaceutically acceptable salt thereof for the manufacture of a hypotensive agent.
• Hypertension is a disease showing the rising of blood pressure due to the increase of resistance of peripheral resistance vessel accompanied to functional or organic change, and is generally divided into two categories, i.e. essential hypertension and secondary hypertension according to the origin thereof.
• hypotensive agents which are used in the treatment of these hypertensions, such as vasodilators (e.g. hydralazine, etc.), adrenoceptor blockers including ⁇ -blockers (e.g. prazosin, etc.), and ⁇ -blockers (e.g. pindrol, etc.), angiotensin converting enzyme inhibitors (e.g. captopril, etc.), calcium antagonists (e.g. nifedipine, etc.), and diuretics (e.g. hydrochlorothiazide, etc.).
• vasodilators e.g. hydralazine, etc.
• adrenoceptor blockers including ⁇ -blockers (e.g. prazosin
• EP-A-0 268 800 discloses a diuretic pharmaceutical composition comprising a phenoxyacetic derivative of the formula (I) or a salt thereof and a pharmaceutically acceptable carrier therefor. None can be found in this reference that the compounds are also valuable for the manufacture of a hypotensive agent.
• the phenoxyacetic acid derivatives (I) and pharmaceutically acceptable salts thereof, which are the active ingredient for use in the preparation of the hypotensive agent have an excellent hypotensive activity.
• SHR spontaneously hypertensive rats
• the systolic blood pressure of the rats in the test compound-administered group wherein [2,3-dichloro-4-(1-ethoxymethyl-5-pyrazolylcarbonyl)phenoxy]acetic acid and [2,3-dichloro-4(1-ethyl-5-pyrazolylcarbonyl)phenoxy]acetic acid were used as the active ingredient, showed a decrease of about 13 % 2 hours after administration in comparison with that of before administration.
• phenoxyacetic acid derivatives useful as the active ingredient in the hypotensive agent are the compounds of the formula (I) wherein X is a halogen atom such as chlorine or bromine atom, and among them, preferable compounds are the compounds of the formula (I) wherein R is an alkyl group of 1 to 4 carbon atoms or an alkyl group of 1 to 3 carbon atoms substituted by an alkoxy group of 1 to 3 carbon atoms, and X is chlorine atom.
• Particularly preferable compounds are the compounds of the formula (I) wherein R is an ethyl group or an ethoxymethyl group and X is chlorine atom, more specifically the following compounds: [2,3-dichloro-4-(1-ethoxymethyl-5-pyrazolylcarbonyl)phenoxy]acetic acid [2,3-dichloro-4-(1-ethyl-5-pyrazolylcarbonyl)phenoxy]acetic acid.
• the phenoxyacetic acid derivatives (I) and the pharmaceutically acceptable salts thereof show an excellent hypotensive activity and hence, can be used in the treatment and prophylaxis of essential hypertension and various secondary hypertensions such as renal hypertension, endocrine hypertension, cardiovascular hypertension, hypertension accompanied to pregnancy, hypertension accompanied to acute stress, hypertension due to drugs, and alcoholic hypertension and the other hypertensions.
• the phenoxyacetic acid derivatives (I) can be used either in the free form or in the form of a pharmaceutically acceptable salt thereof, and suitable examples of the pharmaceutically acceptable salt of the compound (I) are alkali metal salts (e.g. sodium salt or potassium salt), alkaline earth metal salts (e.g. calcium salt), inorganic acid salts (e.g. hydrochloride or hydrobromide) and organic acid salts (e.g. methanesulfonate or oxalate).
• alkali metal salts e.g. sodium salt or potassium salt
• alkaline earth metal salts e.g. calcium salt
• inorganic acid salts e.g. hydrochloride or hydrobromide
• organic acid salts e.g. methanesulfonate or oxalate
• the hypotensive agent can be administered either orally or parenterally.
• the hypotensive agent can be used in the form of a pharmaceutical preparation which may contain pharmaceutical carriers suitable for oral administration such as vehicles, binders, disintegrators and wetting agents.
• the pharmaceutical carriers include, for example, starch, lactose, glucose, gelatin, sorbitol, tragacanth, polyvinylpyrrolidone, sugar, corn starch, polyethylene glycol, talc, potassium phosphate, magnesium stearate, and the other conventional vehicles, binders or disintegrators and wetting agents.
• the pharmaceutical preparation may be used in the solid dosage form such as tablets, powders, capsules, granules and the like or in the liquid dosage form such as solutions, suspensions, emulsions, syrups or elixirs.
• the pharmaceutical preparation when administrated parenterally, is preferably used in the form of injections.
• suitable examples of solvents for the preparation for injections are distilled water for injection, vegetable oil or propylene glycol.
• the pharmaceutical preparation for injections may contain safe solubilizers, buffer agents, stabilizers, and the like.
• the dose of the compound (I) or a pharmaceutically acceptable salt thereof in the hypotensive agent may vary depending on the administration routes, the age, body weight or condition of patients and the kinds of diseases to be treated.
• the preferred dose of the compound (I) or a salt thereof is usually in the range of 1 to 200 mg/kg/day, especially 3 to 100 mg/kg/day.
• the phenoxyacetic acid derivatives (I) can be prepared, for example, by reacting a phenol derivative of the formula: wherein R and X are the same as defined above, with an acetic acid compound of the formula: Y-CH2COOR1, wherein Y is a halogen atom and R1 is a lower alkyl group, to give a phenoxyacetic acid ester derivative of the formula: wherein R1, R and X are the same as defined above, and subsequently by subjecting the said phenoxyacetic acid ester derivative to hydrolysis by the conventional method.
• a suspension of a test compound in water containing a small amount of Tween 80 was administered orally in a volume of 1 ml/100 g of rat's weight (a dose of the test compound: 200 mg/kg) to SHR (about 40 weeks old, 4 to 6 rats/group) fasted overnight.
• the blood pressure before and after administration of the test compound were measured noninvasively by the tail-cuff method, and estimated the rate of the change of the blood pressure 2 hours after administration of the test compound against the blood pressure before administration of the test compound. In both of test compound No. (1) and No. (2), the rate of change of the blood pressure was about -13 %.
• a left kidney was taken out from male SD rats (6 weeks old, weight; about 200 g, 10 rats/group), and 1 week later, silicon resin containing 150 mg/kg of deoxycorticosterone acetic acid (DOCA) was embedded in subcutaneous tissue at the back of each rat under ether anesthesia. After operation, the rats were provided with water containing 1 % sodium chloride and 0.2 % potassium chloride as drinking water in order to produce DOCA-salt rats.
• DOTA deoxycorticosterone acetic acid
• a suspension of the test compound (1) in water containing a small amount of Tween 80 was administered orally in a volume of 10 ml/kg (a dose of the test compound: 100 mg/kg/day) once a day for 4 weeks to SHR (5 weeks old, weight; about 100 g, 10 rats/group) in the test compound-administered group.
• the same amount of water containing a small amount of Tween 80 was administered to the rats in control group instead of the suspension of the test compound (1).
• the systolic blood pressure of rats of the both groups was measured once a week until the fifth week by the tail-cuff method. The results are shown in the following Table 2.
• the blood pressure of rats in the test compound-administered group was decreased significantly from the first week after administration in comparison with the blood pressure of the rats in control group.
• the DOCA-salt loaded rats being in the stable hypertensive condition were obtained by feeding the DOCA-salt loaded rats used in Experiment 2 with tap water instead of aqueous salt solution for 6 weeks.
• these established DOCA-salt hypertensive rats (8 rats/group), the same experiments were carried out as Experiment 3 except that the dose of the test compound (1) was 50 mg/kg/day, the period of administration was 3 weeks, and the systolic blood pressure was measured until the fourth week after administration.
• the results are shown in the following Table 4.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (1)

Publications (2)

Family

ID=13073614

Family Applications (1)

Country Status (2)

Family Cites Families (1)

• 1989
  • 1989-02-09 JP JP1030881A patent/JPH01316317A/ja active Granted
  • 1989-08-29 EP EP89115881A patent/EP0414931B1/en not_active Expired - Lifetime

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events